Overview

A Non Interventional Study To Asses The Safety, Effectiveness And Tolerability Of Quinapril (Acupil®) In An Indian Population

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
0
Participant gender:
All
Summary
This is a prospective, non-interventional, non comparative drug study. The efficacy of Quinapril in Asian population has been evaluated, but specifically in Indian patients the data is sparse. Data in a real world setting in a large population of Indian patients would shed more light on the safety, tolerability and effectiveness of Quinapril in the Indian population.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Quinapril
Criteria
Inclusion Criteria:

- Patients already on therapy with Acupil® for a minimum period of 4 weeks, Evidence of
a personally signed and dated informed consent document

Exclusion Criteria:

- Patients having a Week 0 visit blood pressure reading of more than 180/110 mm of Hg
will not be eligible to participate in the study.

- Women of child bearing age, not willing to use contraceptives, will not be eligible
for the study

- Women using oral contraceptives will also not be included in the study

- Patients who have received any drug other than Acupil® as the first prescribed
antihypertensive would not be eligible for enrollment into the trial

- Patients having any complication at Week 0 visit which would require more thorough
investigations or who required more than one anti-hypertensive drug at the time of
initiation of their therapy will not be included in the study

- Patients having any contraindications as per the LPD of Acupil®